January 9, 2025
CAGE Bio Announces Phase 2b Trial for CGB-500 (1% Tofacitinib), a Breakthrough Topical JAK Inhibitor
San Carlos, CA; Fort Worth, TX
Event Details
January 9, 2025
CAGE Bio Announces Phase 2b Trial for CGB-500 (1% Tofacitinib), a Breakthrough Topical JAK Inhibitor
San Carlos, CA; Fort Worth, TX
August 03, 2023
CAGE Bio Announces Positive Topline Results From its Double-Blind Phase 2 Study Evaluating an Ionic
San Carlos, CA; Fort Worth, TX
Event Details
August 03, 2023
CAGE Bio Announces Positive Topline Results From its Double-Blind Phase 2 Study Evaluating an Ionic
San Carlos, CA; Fort Worth, TX
SEPTEMBER 15, 2022
CAGE Bio, TAGCyx, and PeptiStar Announce License Agreement for Dev & Comm. of TAGX-0003
San Carlos, CA; Fort Worth, TX
Event Details
SEPTEMBER 15, 2022
CAGE Bio, TAGCyx, and PeptiStar Announce License Agreement for Dev & Comm. of TAGX-0003
San Carlos, CA; Fort Worth, TX
May 11, 2021
CAGE Bio Initiates Phase 2 Study for Treatment of Rosacea
San Carlos, CA; Fort Worth, TX
Event Details
May 11, 2021
CAGE Bio Initiates Phase 2 Study for Treatment of Rosacea
San Carlos, CA; Fort Worth, TX
February 16, 2021
CAGE Bio Closes $7.2 Million Round of Series A Funding
San Carlos, CA; Fort Worth, TX
Event Details
February 16, 2021
CAGE Bio Closes $7.2 Million Round of Series A Funding
San Carlos, CA; Fort Worth, TX
More Events
Copyright © 2020 CAGE Bio Inc. - All Rights Reserved.
This website uses cookies.
We use cookies to analyze website traffic and optimize your website experience. By accepting our use of cookies, your data will be aggregated with all other user data.
Welcome! Check out our latest news.
CAGE Bio Announces Phase 2b Trial for CGB-500 (1% Tofacitinib), a Breakthrough Topical JAK Inhibitor for Moderate to Severe Atopic Dermatitis